Ally Financial Inc. Invests $2.35 Million in Edwards Lifesciences Corporation $EW

Key Points

• Ally Financial acquired 26,000 Edwards Lifesciences shares during the second quarter, worth approximately $2.35 million. Institutional investors own 79.46% of EW’s outstanding stock.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 in EPS versus the $0.74 consensus estimate and $1.74 billion in revenue, up 13.6% year over year.
• Analysts maintain a positive outlook, with 17 Buy ratings and six Holds, producing a “Moderate Buy” consensus and an average price target of $100.27. However, company insiders sold 25,570 shares worth about $2.22 million over the past 90 days.

Ally Financial Inc. acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 26,000 shares of the medical research company's stock, valued at approximately $2,352,000.

Other hedge funds also recently made changes to their positions in the company. Rehmann Capital Advisory Group lifted its holdings in shares of Edwards Lifesciences by 2.1% in the 4th quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company's stock worth $546,000 after acquiring an additional 130 shares during the last quarter. McIlrath & Eck LLC grew its holdings in shares of Edwards Lifesciences by 14.6% during the 4th quarter. McIlrath & Eck LLC now owns 1,057 shares of the medical research company's stock valued at $90,000 after purchasing an additional 135 shares during the last quarter. Quadrant Capital Group LLC raised its position in Edwards Lifesciences by 0.9% in the 4th quarter. Quadrant Capital Group LLC now owns 15,113 shares of the medical research company's stock worth $1,288,000 after purchasing an additional 136 shares during the period. Stephens Inc. AR raised its position in Edwards Lifesciences by 5.4% in the 4th quarter. Stephens Inc. AR now owns 2,799 shares of the medical research company's stock worth $239,000 after purchasing an additional 144 shares during the period. Finally, Composition Wealth LLC lifted its stake in Edwards Lifesciences by 1.6% in the fourth quarter. Composition Wealth LLC now owns 9,331 shares of the medical research company's stock worth $795,000 after purchasing an additional 147 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of the business's stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 23,145 shares of the business's stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 25,570 shares of company stock valued at $2,219,390 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Edwards Lifesciences Trading Up 0.1%

NYSE:EW opened at $89.89 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77. The firm has a market capitalization of $51.76 billion, a price-to-earnings ratio of 51.66, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The business has a fifty day moving average price of $89.21 and a 200-day moving average price of $84.68.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the company earned $0.67 earnings per share. The business's revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on EW shares. Piper Sandler reissued an "overweight" rating and set a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research note on Friday, July 24th. JPMorgan Chase & Co. boosted their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Friday, July 24th. Citigroup lifted their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, July 8th. Mizuho boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an "outperform" rating in a research note on Wednesday, July 15th. Finally, Barclays restated an "overweight" rating and set a $110.00 target price (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average price target of $100.27.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source